Fu et al. have indicated that the vasoactive intestinal polypeptide type-I receptor (VIPR1) is decreased in HCC and that VIPR1 inhibits HCC growth by regulating the phosphorylation of the mTOR pathway as well as pyrimidine biosynthesis [94]. This evidence concerns the gene VIPR1 and hepatocellular carcinoma.